Spectrum Pharmaceuticals acquires, develops and commercializes a broad and diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options.
The company's pipeline includes promising early and late-stage drug candidates with unique formulations and mechanisms of action that address the needs of seriously ill patients, such as new treatment regimens for refractory disease.
Spectrum has a broad and diversified portfolio of proprietary drugs in various stages of development in the fields of oncology and urology. Spectrum engages in important collaborations with other drug companies.
Recently in-licensed Belinostat, a novel HDAC inhibitor is being evaluated in multiple opportunities, including a study for PTCL.
Apaziquone (Eoquin®), a synthetic Bio-reductive prodrug, is being investigated in the treatment of non-invasive bladder cancer. We recently completed the enrollment of 1,600 patients into the two Phase 3 studies that began in early 2007. We expect to see top-line data in the first half of 2012.
Spectrum also has three drugs in the Phase 2 stage of development: Ozarelix, for the treatment of prostate cancer and benign prostatic hypertrophy, Ortataxel, for the treatment of taxane-refractory tumors, and Satraplatin, a Phase 2 oral, anti-cancer drug, being investigated for non-small cell lung cancer (NSCLC).
The Company has three drugs in the Phase 1 stage of development: SPI-1620, an adjunct to chemotherapy, Elsamitrucin, which will target advanced solid tumors and Lucanthone, a chemotherapy sensitizer in the treatment of recurrent, malignant brain tumors.
Other drugs in development include RenaZorb™, used in the treatment of hyperphosphotemia in end stage renal disease (ESRD), and SPI-205 for chemotherapy induced neuropathy.
For detailed information regarding these drugs, please select from the list below.